Welcome to our dedicated page for Oncternal Therapeutics news (Ticker: ONCT), a resource for investors and traders seeking the latest updates and insights on Oncternal Therapeutics stock.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) is a clinical-stage biopharmaceutical company dedicated to developing innovative oncology therapies targeting cancers with significant unmet medical needs. The company's diverse product pipeline aims to address a wide range of malignancies, advancing novel therapeutic approaches with the potential to significantly improve patient outcomes.
One of Oncternal's flagship products is zilovertamab, a humanized monoclonal antibody that targets the receptor-tyrosine kinase-like orphan receptor 1 (ROR1). Currently in Phase 1/2 clinical trial, zilovertamab is being tested in combination with ibrutinib for mantle cell lymphoma and chronic lymphocytic leukemia, as well as in combination with paclitaxel for HER2-negative metastatic breast cancer.
Another key product in the pipeline is ONCT-216, a small molecule designed to inhibit ETS-family oncoproteins. ONCT-216 is undergoing Phase 1 trials to treat Ewing sarcoma, among other potential indications.
Oncternal is also developing ONCT-808, a CAR-T cell therapy targeting ROR1, showing promise in preclinical models against various hematological malignancies and solid tumors. Furthermore, ONCT-534, a dual-action androgen receptor inhibitor, is in Phase 1/2 trials for advanced prostate cancer, addressing resistance mechanisms common in patients who have relapsed after standard treatments.
Financially, Oncternal remains robust, with ongoing clinical trials supported by solid operational funding. The company maintains strategic partnerships and collaborations to foster innovation and expedite the development of its therapeutic candidates. With a focus on unmet medical needs, Oncternal Therapeutics is at the forefront of oncology research, aiming to bring new hope to patients worldwide.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced promising interim results from a Phase 1b trial of cirmtuzumab combined with paclitaxel in HER2-negative breast cancer, showing a 57% partial response rate among evaluable patients. In preclinical studies, cirmtuzumab demonstrated single-agent efficacy and enhanced effects with standard chemotherapies against high-grade serous ovarian and endometrial cancers. Additionally, investigational selective androgen receptor degraders showed inhibition of tumor growth in androgen receptor-positive triple-negative breast cancer models. The company continues to advance its clinical programs.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced the granting of an inducement award to new Senior VP of Human Resources, Anita Wiseth, on March 18, 2021. The award includes options for 90,000 shares at an exercise price of $8.36, vesting over four years. This grant, part of Oncternal’s 2021 Employment Inducement Incentive Award Plan, was approved by an independent compensation committee in compliance with Nasdaq regulations. The company focuses on developing novel oncology therapies targeting significant unmet medical needs.
Oncternal Therapeutics (Nasdaq: ONCT) reported encouraging interim results for cirmtuzumab combined with ibrutinib in its ongoing Phase 1/2 study for mantle cell lymphoma (MCL), showing a 47% complete response (CR) rate versus a historical 20% CR. The company is advancing ROR1-targeting CAR-T therapies and has two durable responses reported in Ewing sarcoma patients treated with TK216. Financially, Oncternal raised $125 million in 2020 to support its pipeline, with a net loss of $17.2 million for the year and $116.7 million cash on hand as of December 31, 2020.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) will report its fourth quarter and full year 2020 financial results on March 11, 2021, post-market. A webcast will follow at 2:00 p.m. PT for management to discuss the results and provide a business update. Oncternal is focused on developing novel oncology therapies addressing unmet medical needs, with ongoing clinical studies for cirmtuzumab and TK216. The company's primary aim is to tap into promising biological pathways involved in cancer progression.
Oncternal Therapeutics (Nasdaq: ONCT) will participate in two significant virtual conferences in March 2021. The first is the H.C. Wainwright Global Life Sciences Conference on March 9, starting at 7:00 AM ET, with James Breitmeyer presenting. The second event is the Oppenheimer 31st Annual Healthcare Conference on March 16, at 4:30 PM ET, also featuring Breitmeyer. Both presentations will be available for streaming, and links can be found on Oncternal's investor website. The company focuses on developing innovative oncology therapies.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced the granting of an inducement award to Christy Stolzer, its new Associate Director of Drug Safety, on February 22, 2021. The award includes options to purchase 60,000 shares of common stock at an exercise price of $7.20 per share, vesting over four years. This grant adheres to Oncternal's 2021 Employment Inducement Incentive Award Plan, aimed at attracting new employees. The options were approved by the independent compensation committee as required by Nasdaq regulations.
Oncternal Therapeutics appointed Dr. Rosemary Mazanet to its Board of Directors, effective January 27, 2021. She brings extensive oncology drug development experience, having led initiatives at Amgen and serving in leadership roles in various biopharma companies. Dr. Mazanet's expertise is expected to enhance Oncternal's ongoing projects, including cirmtuzumab and ROR1 CAR-T programs. Oncternal focuses on innovative oncology therapies targeting unmet medical needs, with clinical trials underway for its candidates.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced a partnership with Lentigen Technology to manufacture lentiviral vectors for its ROR1-targeting CAR-T cell therapy program. The agreement aims to accelerate the development of this innovative cancer treatment, with GMP manufacturing reserved for 2021. Oncternal's President noted the significance of ROR1 as a target in oncology, with plans to achieve first-in-human dosing in the latter half of 2021. This collaboration underscores Oncternal's commitment to advancing cancer therapies with high unmet medical needs.
Oncternal Therapeutics (Nasdaq: ONCT) announced a collaboration with Karolinska Institutet in Sweden to develop ROR1-targeting cell therapies, enhancing their CAR-T and CAR-NK programs. This partnership includes IND-supporting preclinical studies led by Evren Alici, M.D., in the NextGenNK Center. The collaboration aims to leverage Oncternal's cirmtuzumab in developing novel cancer treatment options for hematologic and solid tumors. ROR1 is recognized as a promising target for these therapies, potentially leading to improved efficacy and safety in patient treatments.
Oncternal Therapeutics (Nasdaq: ONCT) announced participation of CEO James Breitmeyer in a fireside chat at H.C. Wainwright's BioConnect 2021 Conference on January 11, 2021. The discussion will highlight Oncternal's recent progress, upcoming catalysts, and strategies for 2021. The session will be available on-demand starting at 6am EST and will be accessible via a webcasting link. Oncternal focuses on developing novel oncology therapies with unmet medical needs, including investigational drugs cirmtuzumab and TK216, aimed at treating various cancers.
FAQ
What is the current stock price of Oncternal Therapeutics (ONCT)?
What is the market cap of Oncternal Therapeutics (ONCT)?
What does Oncternal Therapeutics specialize in?
What are the key products in Oncternal's pipeline?
What is zilovertamab?
What is ONCT-534?
How is Oncternal funded?
What makes ONCT-808 unique?
What is the significance of ONCT-216?
What are the current clinical trials for Oncternal's products?
Where can I find more information about Oncternal Therapeutics?
How does Oncternal aim to address unmet medical needs?
